Dementia and Alzheimer Disease

Although research illustrates the persistence of inequities between women and men in neurology, 3 women leaders shared encouraging thoughts and experiences highlighting the progress made in recent years.

Collaboration can result in greater success than what one can achieve alone, and for women physicians, this rings truer than ever before, writes Jill M. Farmer, DO, MPH.

In light of National Women Physicians Day, the assistant clinical professor at Vanderbilt University School of Medicine commented on the roles women have played historically, and her perspective on where they stand now. [WATCH TIME: 12 minutes]

Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.

Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The cognitive neurologist at the University of California, San Francisco provided insight on the research needed to explain more about COVID-19’s pathogenesis and the realistic possibility of developing neurocognitive disorders.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of AD.

An expert explains the role biomarker testing plays when diagnosing a patient with AD.

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

The cognitive neurologist at the University of California, San Francisco discussed a specific analysis that evaluated differences in cerebrospinal fluid in patients who develop cognitive changes following COVID-19 infection. [WATCH TIME: 6 minutes]

Regardless of baseline body mass index, patients who had increases or decreases of 5% or more in BMI had faster cognitive decline over a 5-year follow-up period.

The association was found independent of vascular risk factors, suggesting a dose-response association between stroke severity and recurrence with risk of dementia.

Discussing recent technological advancements in the AD field, the founding executive director of the Alzheimer’s Drug Discovery Foundation noted the doors that these innovations have opened. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on the potential to detect patients at-risk for Alzheimer disease at an earlier age. [WATCH TIME: 4 minutes]

In addition to improving constipation in patients with Parkinson disease, ENT-01 also helped improve Mini-Mental State Examination scores, an exploratory measure of cognition.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2022 that neurology health care professionals should keep their eyes on.

The cognitive neurologist at the University of California San Francisco discussed whether Alzheimer disease is a realistic fear for patients who’ve contracted COVID-19. [WATCH TIME: 5 minutes]

The light intervention was found to reduce awakening time at night, delay sleep offset, and advance sleep onset in a small patient population with dementia.

The founding executive director of the Alzheimer’s Drug Discovery Foundation spoke on the potential of drugs in the neuroprotection class for treatment of patients with AD. [WATCH TIME: 5 minutes]